Reps. Eliot Engel, D-N.Y., and Larry Bucshon, R-Ind., have introduced the Advancing Education on Biosimilars Act of 2019, which would create federal programs to promote the use of use cost-effective biosimilar drugs. Among other areas, the AHA-supported bill would require the Food and Drug Administration to create a public website to educate patients and providers about biological and biosimilar products. The website will include materials about which biologicals and biosimilars may be interchangeable, and processes for reporting adverse events that pose a risk to patient health and safety. The bill also will require development of continuing education programs for health care providers. “America’s hospitals and health systems thank Reps. Engel and Bucshon for their bipartisan efforts to facilitate the increased use of biosimilar drugs, including the importance of interchangeability, by educating providers, patients and other key stakeholders on their clinical value,” said AHA Executive Vice President Tom Nickels. “This will give patients greater access to affordable, innovative drugs.” Sens. Mike Enzi, R-Wyo., and Maggie Hassan, D-N.H., earlier this year introduced companion legislation that was included in S. 1895, the Lower Health Care Costs Act, that passed the Senate Committee on Health, Education, Labor and Pensions in June.

Related News Articles

Blog
Tom Nickels, AHA executive vice president, responds to a PhRMA-funded study that attempts to deflect blame for a growing crisis of their own making – the…
Headline
Kansas Gov. Laura Kelly has reached agreement with Senate Republicans on a bipartisan proposal to expand Medicaid eligibility to low-income uninsured adults by…
Headline
The Centers for Medicare…
Headline
The Senate today voted 71-23 to pass legislation (H.R. 1865) funding the Department of Health and Human Services and other non-Defense agencies for fiscal year…
Headline
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2018 data.
Blog
The pharmaceutical industry’s latest “report” is an obvious attempt to divert attention away from a problem of their own making: skyrocketing drug prices.